Sigilon Therapeutics to Host Interactive Webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Dec. 4, 2017
Presentations by Robert Langer and Daniel Anderson Followed by Interactive Q&A Session Open to the Public Moderated by Journalist Luke Timmerman
CAMBRIDGE, Mass., Nov. 30, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that it will host a live, online educational webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Monday, Dec. 4, 2017, at 10 a.m. EST. Following presentations by Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Sigilon scientific advisory board, journalist Luke Timmerman will moderate a discussion of questions submitted by audience participants on current methods and promising new protein delivery technologies.
“Significant progress continues to be made towards the development of therapeutic technologies that can replace or produce proteins from within the body,” said Dr. Langer. “Our goal is to restore the natural protein function in the body and thereby provide significant therapeutic benefits to patients.”
The presentations will review current methods of protein delivery, provide historical background on the development of new methods, and compare methods including gene therapy, gene editing and implanted engineered cell therapies that are related to the academic and translational research of Dr. Langer and Dr. Anderson. Participation is open to members of the public at no cost.
Participants can register in advance and access the webinar at: https://www.webcaster4.com/Webcast/Page/754/23361. Participants are encouraged to log on within 15 minutes prior to the beginning of the webinar. Following the event, a replay of the event will be available on the Sigilon website.
About Sigilon Therapeutics
Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.
In addition to Flagship Pioneering, Sigilon Therapeutics’ co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.